Thursday, December 29, 2022

Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen

The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”

from NYT > Top Stories https://ift.tt/jYOPTCi
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Oscars Will Move to a Venue Outside Hollywood

The event will be held in downtown Los Angeles starting in 2029 as part of a deal between the academy and AEG, a developer of entertainment ...